NRG1 and non-small cell lung carcinoma: In the currently ongoing phase II eNRGy trial (NCT02912949), 35% of 46 evaluable patients with NRG1 fusion-positive NSCLC who had progressed after standard therapy had an objective response to zenocutuzumab (MCLA-128; Zeno).